Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study Academic Article uri icon

Overview

MeSH Major

  • Lymphoma, B-Cell
  • Nitrogen Mustard Compounds

abstract

  • Single-agent bendamustine produced a high rate of objective responses with acceptable toxicity in patients with recurrent, rituximab-refractory indolent B-cell lymphoma.

publication date

  • January 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2916680

Digital Object Identifier (DOI)

  • 10.1002/cncr.24714

PubMed ID

  • 19890959

Additional Document Info

start page

  • 106

end page

  • 14

volume

  • 116

number

  • 1